


# ATS 2026 Preview – Clinical and AI / ML



**LucidQuest Intelligence**  
Accelerate your success

 **ATS 2026**

Pre-Conference May 15&16  
International Conference May 17-20  
Orlando, FL

# ATS 2026 Preview – Table of Contents

- [New Trends In Pulmonary and Respiratory Medicine At ATS'26 3-5](#)
- [Key Sessions To Watch 6](#)
- [Industry-sponsored Sessions & Focus Areas At ATS 2026 7-15](#)
  - [Competitive Landscape At a Glance at ATS 2026 8-9](#)
  - [Key Industry-sponsored Sessions At ATS 2026 10-15](#)
  - [New Entrants 16](#)
- [AI/ML Trends & Strategic Watchpoints At ATS 2026 17-19](#)
  - [AI / DIGITAL HEALTH ANGLE At ATS 2026 18-19](#)
- [What We're Watching For Post-congress 20](#)
- [Get In Touch With LucidQuest 21](#)





- **COPD biologics will test whether biomarker-defined segmentation can move beyond inhaled therapy**

- ATS 2026 will place COPD biologic competition under direct scrutiny through itepekimab AERIFY-1/2 data, AstraZeneca's tozorakimab/IL-33 positioning, and GSK's eosinophilic COPD focus. The strategic question will be whether COPD treatment remains anchored in inhaled escalation or shifts toward biologic selection based on IL-33 biology, eosinophils, and Type 2 inflammatory signals



- **IPF and PPF differentiation will increasingly depend on subgroup utility and sequencing logic**

- Boehringer's JASCAYD®/nerandomilast programming, BMS fibrosis education, admilparant/BMS-986278 context, and inhaled treprostinil PPF data will keep antifibrotic strategy in focus. The key question will be whether companies can defend value through subgroup performance, tolerability, sequencing, or patient burden rather than FVC decline alone



- **IL-33 will emerge as a contested mechanism across obstructive airway disease**

- Sessions involving itepekimab, tozorakimab, ST2/IL-33 biology, and epithelial cytokine pathways will suggest that IL-33 is becoming a mechanism-level battleground in COPD and asthma. The competitive tension will center on whether IL-33 blockade can be differentiated through exacerbation reduction, mucus biology, epithelial inflammation, or COPD–asthma overlap positioning



- **Bronchiectasis will shift from an underdiagnosed condition to an active launch-shaping market**

- Insmed's BRINSUPRI®/brensocatib sessions, bronchiectasis diagnostic-gap programming, home high-flow therapy data, and MAC/NTM late-breaking content will place NCFB care pathways under scrutiny. The unresolved question will be whether future management becomes drug-led, infection-led, airway-clearance-led, or structured around earlier diagnosis and exacerbation-risk stratification





- **PAH competition will shift toward sotatercept sequencing and real-world optimization**

- ATS 2026 is expected to feature multiple sotatercept-focused sessions across CTD-associated PAH, double-background therapy, early-access experience, hemodynamic heterogeneity, and comorbid populations. The key competitive question will be whether WINREVAIR/sotatercept moves earlier in the treatment pathway or remains focused on specialist-managed, higher-risk patients



- **AI and digital respiratory tools will gain relevance where they influence clinical workflow**

- ATS 2026 will include AI and digital sessions focused on CT-based PH screening, ILD phenotyping, lung nodule risk, COPD prediction, fibrosis quantification, and remote monitoring. The signal will not be generic digital innovation; it will be whether these tools can alter diagnosis timing, trial enrichment, referral pathways, or longitudinal monitoring in respiratory care





# Key Sessions To Watch

| Date        | Session Title (short)                                              | Type                         | Author / Institution                                | Why Watch                                                                                             |
|-------------|--------------------------------------------------------------------|------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 17 May 2026 | Sotatercept in CTD-associated PAH                                  | Mini Symposium               | Rogério Souza / University of São Paulo             | Clarifies sotatercept relevance in a clinically difficult PAH subgroup                                |
| 17 May 2026 | French early access experience with sotatercept                    | Mini Symposium               | David Montani / AP-HP                               | Provides real-world context beyond pivotal trial data                                                 |
| 18 May 2026 | Efdoralprin alfa vs plasma-derived A1PI in AATD                    | Mini Symposium               | Igor Barjaktarevic / Los Angeles                    | Tests whether AAT restoration can challenge current augmentation framing                              |
| 18 May 2026 | Itepekimab AERIFY-1/2 in former-smoker COPD                        | Late Breaking Mini Symposium | Klaus F. Rabe / LungenClinic Grosshansdorf          | Direct readout for IL-33 blockade in COPD and Regeneron/Sanofi's biologic positioning                 |
| 18 May 2026 | Nintedanib in children and adolescents with fibrosing ILDs         | Late Breaking Mini Symposium | Robin R. Deterding / University of Colorado         | Expands antifibrotic evidence into pediatric fibrosing ILD                                            |
| 18 May 2026 | Home high-flow therapy in severe bronchiectasis                    | Late Breaking Mini Symposium | Ryosuke Hirabayashi / Kobe City Medical Center      | Could influence non-drug bronchiectasis care alongside BRINSUPRI® launch shaping                      |
| 18 May 2026 | All-oral bedaquiline-based regimen for refractory MAC lung disease | Late Breaking Mini Symposium | Kozo Morimoto / Japan Anti-Tuberculosis Association | Relevant to NTM/MAC treatment strategy and bronchiectasis-associated infection management             |
| 18 May 2026 | Blood-based lung cancer screening test in primary care             | Late Breaking Mini Symposium | James M. Davis / Duke University                    | Tests whether blood-based screening can alter lung cancer referral and detection pathways             |
| 18 May 2026 | Tozorakimab and IL-33-related COPD biology                         | Mini Symposium               | Mateusz Rytelowski / AstraZeneca                    | Supports AstraZeneca's attempt to connect IL-33 blockade with COPD inflammation and mucus dysfunction |



# Industry-Sponsored Sessions & Focus Areas – ATS 2026





# ATS 2026– Competitive Landscape at a Glance (1/2)

| Name                                   | Sessions | Companies / Assets                                                                                 | Why It Matters                                                                                                              |
|----------------------------------------|----------|----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| COPD biologics and Type 2 inflammation | Multiple | Regeneron/Sanofi / itepekimab; AstraZeneca / tozorakimab; GSK / mepolizumab                        | COPD competition is shifting from inhaled optimization to biomarker-defined biologic positioning                            |
| IL-33 / epithelial cytokine targeting  | Multiple | AstraZeneca; Genentech; Amgen/AstraZeneca; Regeneron/Sanofi                                        | IL-33 is being tested as a broader airway-disease mechanism across COPD, asthma, CRSwNP, and infection-related inflammation |
| IPF / PPF antifibrotic strategy        | Multiple | Boehringer / JASCAYD® nerandomilast; BMS / IPF–PPF programming; admilparant/BMS-986278; nintedanib | Fibrosis positioning is moving toward subgroup use, tolerability, sequencing, and patient-centered burden.                  |
| Bronchiectasis / NCFB                  | Multiple | Insmed / BRINSUPRI®, brensocatic                                                                   | NCFB is becoming a launch-ready market where diagnosis, exacerbation risk, and infection control will shape adoption        |
| PAH / PH-ILD optimization              | Multiple | Merck / sotatercept; Liquidia / YUTREPIA® treprostinil; inhaled treprostinil studies               | PAH and PH-ILD discussions are moving toward treatment sequencing, delivery fit, and background-therapy selection           |



# ATS 2026– Competitive Landscape at a Glance (2/2)

| Name                                    | Sessions | Companies / Assets                                      | Why It Matters                                                                                                                               |
|-----------------------------------------|----------|---------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| AATD restoration and genetic approaches | Multiple | Sanofi / AAT restoration; efdoralprin alfa; RNA editing | AATD may move beyond augmentation therapy if restoration or genetic-correction approaches show clinical relevance                            |
| AI / imaging / digital monitoring       | Multiple | Qureight; ResMed; Keva Health; academic AI/ML groups    | The digital signal is strongest where tools affect CT interpretation, PH screening, lung nodule risk, COPD prediction, or remote monitoring. |



# Key Industry-Sponsored Sessions at ATS 2026 (1/6)



- **Inhibikase Therapeutics:**

- Focus Areas: PAH & Adaptive Clinical Development
- Presentations will address IKT-001 development and adaptive trial design in pulmonary arterial hypertension



- **Merck:**

- Focus Areas: PAH & Respiratory Product Education
- Discussions will focus on adult PAH evidence, treatment insights, and clinician education



- **Boehringer Ingelheim:**

- Focus Areas: Nerandomilast, ILD & Chronic Lung Disease
- Presentations will cover JASCAYD®, HRCT use, and diagnosis-led respiratory management



# Key Industry-Sponsored Sessions at ATS 2026 (2/6)



- **GSK:**

- Focus Areas: Severe Asthma, Biologics & Triple Therapy
- Sessions will highlight eosinophilic asthma, biologic evidence, escalation strategies, and refractory cough



- **SNJ Pharma:**

- Focus Areas: Pulmonary Embolism Management
- Presentations will address PE diagnosis, risk stratification, and evolving treatment approaches



- **AstraZeneca:**

- Focus Areas: Asthma, COPD & IL-33/ST2 Biology
- Discussions will examine uncontrolled asthma, AIRSUPRA®, COPD inflammation, and phenotype-led care



# Key Industry-Sponsored Sessions at ATS 2026 (3/6)



- **Vertex Pharmaceuticals:**

- Focus Areas: Cystic Fibrosis & Clinical Collaboration
- Sessions will cover CF diagnostic reconsideration and academic-industry translation models



- **4DMedical:**

- Focus Areas: CT-Based Ventilation-Perfusion Mapping
- Presentations will highlight non-contrast pulmonary mapping for CT practice and care pathways



- **BMS:**

- Focus Areas: IPF, PPF & Patient Perspectives
- Discussions will address fibrosing lung disease burden and patient-pulmonologist treatment perspectives



# Key Industry-Sponsored Sessions at ATS 2026 (4/6)



- **Bambusa Therapeutics:**

- Focus Areas: Precision Medicine in COPD
- Presentations will focus on novel COPD treatment strategies and clinical success pathways



- **Chiesi USA:**

- Focus Areas: Small Airway Disease in Asthma
- Discussions will highlight small airway disease recognition in asthma management



- **Amgen/AstraZeneca:**

- Focus Areas: Severe Asthma, CRSwNP & COPD
- Sessions will connect epithelial cytokines across asthma, CRSwNP, and COPD



# Key Industry-Sponsored Sessions at ATS 2026 (5/6)



- **aTyr Pharma:**

- Focus Areas: Research Funding & Pulmonary Innovation
- Discussions will examine funding shifts and respiratory research continuity



- **Insmed:**

- Focus Areas: Bronchiectasis, NCFB & Monitoring
- Sessions will cover BRINSUPRI®, diagnostic gaps, and chronic respiratory care



- **Eli Lilly:**

- Focus Areas: Tirzepatide & Biomarker-Driven NSCLC
- Discussions will cover Zepbound® use, obesity-linked respiratory risk, and biomarker-led NSCLC care



# Key Industry-Sponsored Sessions at ATS 2026 (6/6)



- **Genentech:**

- Focus Areas: COPD & ST2/IL-33 Pathway
- Presentations will examine inflammatory pathway biology in COPD management



- **Regeneron and Sanofi:**

- Focus Areas: COPD Biologics, Type 2 Inflammation & Asthma/COPD Outcomes
- Sessions will examine biologic evidence, type 2 inflammation in COPD, and clinical outcomes across asthma and COPD



- **Sanofi:**

- Focus Areas: AATD, Severe Asthma & Eosinophilic Disease
- Presentations will cover AAT restoration, asthma beyond inhalers, and eosinophilic inflammation



# New Entrants

| Asset / Company          | 2026 Presence                                                            |
|--------------------------|--------------------------------------------------------------------------|
| <b>AGMB-447</b>          | Poster Discussion: inhaled lung-restricted TGFβR1/ALK5 inhibitor for IPF |
| <b>Zelicapavir</b>       | Mini Symposium: randomized Phase 2 RSV trial                             |
| <b>EPS-3903</b>          | Thematic Poster: oral STAT6 inhibitor in asthma model                    |
| <b>Resp-x (infex702)</b> | Mini Symposium: positive Phase 2a anti-virulence mAb data                |
| <b>KIT2014</b>           | Poster Discussion: first-in-human inhaled PDE3/4 inhibitor               |
| <b>SIM0722</b>           | Posters: bispecific TSLP/IL-13 antibody and oral STAT6 degrader          |
| <b>Nalbuphine ER</b>     | Mini Symposium + posters: CORAL Phase 2b and RIVER Phase 2a cough data   |
| <b>KB407</b>             | Mini Symposium: interim CORAL-1 trial in cystic fibrosis                 |
| <b>IKT-001</b>           | Poster + Innovation Hub: PAH clinical development program                |



# AI/ML Trends & Strategic Watchpoints at ATS 2026





# AI / Digital Health Angle at ATS 2026 (1/2)

- **AI/ML presentations at ATS 2026 represent a practical respiratory workflow signal, not a generic digital-health theme. The concentration of sessions focused on AI-based imaging, COPD exacerbation prediction, PAH recognition, lung cancer screening, ILD phenotyping, remote monitoring, and wearable sleep diagnostics suggests digital tools are being tested where they could influence diagnosis timing, referral decisions, risk stratification, and longitudinal disease management**
- **AI/ML activity at ATS 2026 will be strategically relevant because it will be focused on clinical decision points in respiratory care, rather than broad analytics. The most important signal will be whether these tools can move from retrospective validation into workflows that affect earlier detection, trial enrichment, specialist referral, and treatment escalation**
- **Key sessions include:**
  - Real-World Use of an AI-Driven Platform Improves Detection and Highlights Challenges in Incidental Lung Nodule Management
  - A Machine Learning Framework for Early Recognition of Pulmonary Arterial Hypertension Using Electronic Health Record Data
  - Utilizing Remote Patient Monitoring on an Artificial Intelligence Platform With Pulmonary Disease Navigator Oversight



# AI / Digital Health Angle at ATS 2026 (2/2)

- **COPD-Gpt:** Transformer-Based Prediction of Exacerbation and Mortality in Chronic Obstructive Pulmonary Disease
- **Deep Learning-derived Fibrotic and Inflammatory Phenotypes** Predict Lung Function Across Idiopathic and Connective-tissue-related Interstitial Lung Disease
- **Deep Learning-based HRCT Assessment of Baseline Disease Severity** in the Deupirfenidone ELEVATE IPF Trial
- **Clinical Utility of Fibresolve**, an Imaging Artificial Intelligence Tool, in the Diagnosis of Idiopathic Pulmonary Fibrosis
- **Management of COPD Patients With Bora Care® Remote Monitoring Solution** Including BVS<sup>3</sup> Early-detection Score
- **Sessions suggest AI is increasingly being used to improve:**
  - Quantitative imaging in ILD, IPF, lung nodules, and pulmonary vascular disease
  - **Risk prediction for COPD exacerbations**, mortality, PAH recognition, and lung cancer screening
  - **Remote monitoring for COPD, asthma**, home ventilation, and long-term respiratory management
  - Trial enrichment through imaging-derived severity, progression markers, and phenotype classification



# What We're Watching for Post-ATS 2026

- Whether **itepekimab AERIFY-1/2 data** demonstrate enough **COPD efficacy** to validate **IL-33 blockade** as a credible **biologic strategy** beyond inhaled escalation pathways
- Whether **AstraZeneca's tozorakimab/IL-33 sessions** show **mechanistic differentiation** versus **Regeneron/Sanofi's itepekimab** and **GSK's eosinophilic COPD positioning**
- Whether **JASCAYD®/nerandomilast subgroup analyses** support meaningful **IPF/PPF differentiation** across **baseline FVC, disease stage, diagnosis timing, and patient burden**
- Whether **BRINSUPRI®/brensocatib data** and **Insmad's bronchiectasis programming** shift **NCFB management** toward **DPP1 inhibition, earlier diagnosis, and exacerbation-risk stratification**
- Whether **AATD restoration approaches**, including **Sanofi's AATD focus, efdoralprin alfa, and RNA-editing sessions**, show enough clinical relevance to challenge plasma-derived augmentation models
- Whether **sotatercept data** across **CTD-associated PAH, double-background therapy, early access experience, and comorbid populations** support broader use beyond high-risk specialist-managed PAH patients

# Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY  
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL  
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS  
DISEASES



INVESTMENT INSIGHTS

e: [INFO@LQVENTURES.COM](mailto:INFO@LQVENTURES.COM)

w: [WWW.LQVENTURES.COM](http://WWW.LQVENTURES.COM)